An Antifungal Combination Matrix Identifies a Rich Pool of Adjuvant Molecules that Enhance Drug Activity against Diverse Fungal Pathogens

Cell Reports

Volumn 13, Issue 7, 2015, Pages 1481-1492

  Robbins, Nicole ^a   Spitzer, Michaela ^a   Yu, Tennison ^a   Cerone, Robert P ^b   Averette, Anna K ^d   Bahn, Yong Sun ^e   Heitman, Joseph ^d   Sheppard, Donald C ^b   Tyers, Mike ^c   Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BENOMYL; CASPOFUNGIN; CLOFAZIMINE; CYPRODINIL; FLUCONAZOLE; TERBINAFINE; ANTIFUNGAL AGENT; DRUG COMBINATION;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL COMBINATION MATRIX; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BIOGENESIS; CANDIDA ALBICANS; CELL MEMBRANE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG DATABASE; FUNGAL STRAIN; FUNGUS ISOLATION; GENE EXPRESSION PROFILING; HETEROZYGOSITY; HYDROPHILICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SACCHAROMYCES CEREVISIAE; SCHIZOSACCHAROMYCES POMBE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; MICROBIAL SENSITIVITY TEST; SCHIZOSACCHAROMYCES;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CLOFAZIMINE; CRYPTOCOCCUS NEOFORMANS; DRUG COMBINATIONS; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; SACCHAROMYCES CEREVISIAE; SCHIZOSACCHAROMYCES;

EID: 84947330410     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.10.018     Document Type: Article

References (38)

1. Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006, 580:5533-5540.
2. Anderson T.M., Clay M.C., Cioffi A.G., Diaz K.A., Hisao G.S., Tuttle M.D., Nieuwkoop A.J., Comellas G., Maryum N., Wang S., et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat. Chem. Biol. 2014, 10:400-406.
3. Blankenship J.R., Steinbach W.J., Perfect J.R., Heitman J. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr. Opin. Investig. Drugs 2003, 4:192-199.
4. Borisy A.A., Elliott P.J., Hurst N.W., Lee M.S., Lehar J., Price E.R., Serbedzija G., Zimmermann G.R., Foley M.A., Stockwell B.R., Keith C.T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA 2003, 100:7977-7982.
5. Brown G.D., Denning D.W., Gow N.A., Levitz S.M., Netea M.G., White T.C. Hidden killers: human fungal infections. Sci. Transl. Med. 2012, 4:165rv13.
6. Brown J.C., Nelson J., VanderSluis B., Deshpande R., Butts A., Kagan S., Polacheck I., Krysan D.J., Myers C.L., Madhani H.D. Unraveling the biology of a fungal meningitis pathogen using chemical genetics. Cell 2014, 159:1168-1187.
7. Butts A., DiDone L., Koselny K., Baxter B.K., Chabrier-Rosello Y., Wellington M., Krysan D.J. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot. Cell 2013, 12:278-287.
8. Antibiotic Resistance Threats in the United States, 2013. U.S. Department of Health and Human Services 2013, Centers for Disease Control and Prevention, CDC.
9. Cholo M.C., Steel H.C., Fourie P.B., Germishuizen W.A., Anderson R. Clofazimine: current status and future prospects. J. Antimicrob. Chemother. 2012, 67:290-298.
10. Cleveland A.A., Farley M.M., Harrison L.H., Stein B., Hollick R., Lockhart S.R., Magill S.S., Derado G., Park B.J., Chiller T.M. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 2012, 55:1352-1361.
11. Costanzo M., Baryshnikova A., Bellay J., Kim Y., Spear E.D., Sevier C.S., Ding H., Koh J.L., Toufighi K., Mostafavi S., et al. The genetic landscape of a cell. Science 2010, 327:425-431.
12. Coste A., Selmecki A., Forche A., Diogo D., Bougnoux M.E., d'Enfert C., Berman J., Sanglard D. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 2007, 6:1889-1904.
13. Cowen L.E., Singh S.D., Köhler J.R., Collins C., Zaas A.K., Schell W.A., Aziz H., Mylonakis E., Perfect J.R., Whitesell L., Lindquist S. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. USA 2009, 106:2818-2823.
14. Davis S.A., Vincent B.M., Endo M.M., Whitesell L., Marchillo K., Andes D.R., Lindquist S., Burke M.D. Nontoxic antimicrobials that evade drug resistance. Nat. Chem. Biol. 2015, 11:481-487.
15. Day J.N., Chau T.T., Wolbers M., Mai P.P., Dung N.T., Mai N.H., Phu N.H., Nghia H.D., Phong N.D., Thai C.Q., et al. Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med. 2013, 368:1291-1302.
16. De Filippi L., Fournier M., Cameroni E., Linder P., De Virgilio C., Foti M., Deloche O. Membrane stress is coupled to a rapid translational control of gene expression in chlorpromazine-treated cells. Curr. Genet. 2007, 52:171-185.
17. Denning D.W., Bromley M.J. Infectious Disease. How to bolster the antifungal pipeline. Science 2015, 347:1414-1416.
18. Fuchs B.B., O'Brien E., Khoury J.B., Mylonakis E. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 2010, 1:475-482.
19. Gene Ontology C. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015, 43:D1049-D1056. Gene Ontology Consortium.
20. Giaever G., Flaherty P., Kumm J., Proctor M., Nislow C., Jaramillo D.F., Chu A.M., Jordan M.I., Arkin A.P., Davis R.W. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. USA 2004, 101:793-798.
21. Gilbert P., Moore L.E. Cationic antiseptics: diversity of action under a common epithet. J. Appl. Microbiol. 2005, 99:703-715.
22. Hill J.A., O'Meara T.R., Cowen L.E. Fitness Trade-Offs Associated with the Evolution of Resistance to Antifungal Drug Combinations. Cell Rep. 2015, 10:809-819.
23. Kuo D., Tan K., Zinman G., Ravasi T., Bar-Joseph Z., Ideker T. Evolutionary divergence in the fungal response to fluconazole revealed by soft clustering. Genome Biol. 2010, 11:R77.
24. LaFayette S.L., Collins C., Zaas A.K., Schell W.A., Betancourt-Quiroz M., Gunatilaka A.A., Perfect J.R., Cowen L.E. PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog. 2010, 6:e1001069.
25. Lee A.Y., St Onge R.P., Proctor M.J., Wallace I.M., Nile A.H., Spagnuolo P.A., Jitkova Y., Gronda M., Wu Y., Kim M.K., et al. Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science 2014, 344:208-211.
26. Levin D.E. Cell wall integrity signaling in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 2005, 69:262-291.
27. Marichal P., Koymans L., Willemsens S., Bellens D., Verhasselt P., Luyten W., Borgers M., Ramaekers F.C., Odds F.C., Bossche H.V. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999, 145:2701-2713.
28. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003, 52:1.
29. Ostrosky-Zeichner L., Casadevall A., Galgiani J.N., Odds F.C., Rex J.H. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 2010, 9:719-727.
30. Pierce S.E., Fung E.L., Jaramillo D.F., Chu A.M., Davis R.W., Nislow C., Giaever G. A unique and universal molecular barcode array. Nat. Methods 2006, 3:601-603.
31. Robbins N., Uppuluri P., Nett J., Rajendran R., Ramage G., Lopez-Ribot J.L., Andes D., Cowen L.E. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 2011, 7:e1002257.
32. Shapiro R.S., Robbins N., Cowen L.E. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol. Mol. Biol. Rev. 2011, 75:213-267.
33. Sharom J.R., Bellows D.S., Tyers M. From large networks to small molecules. Curr. Opin. Chem. Biol. 2004, 8:81-90.
34. Simons V., Morrissey J.P., Latijnhouwers M., Csukai M., Cleaver A., Yarrow C., Osbourn A. Dual effects of plant steroidal alkaloids on Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 2006, 50:2732-2740.
35. Spitzer M., Griffiths E., Blakely K.M., Wildenhain J., Ejim L., Rossi L., De Pascale G., Curak J., Brown E., Tyers M., Wright G.D. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 2011, 7:499.
36. Wilson L.S., Reyes C.M., Stolpman M., Speckman J., Allen K., Beney J. The direct cost and incidence of systemic fungal infections. Value Health 2002, 5:26-34.
37. Yano T., Kassovska-Bratinova S., Teh J.S., Winkler J., Sullivan K., Isaacs A., Schechter N.M., Rubin H. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 2011, 286:10276-10287.
38. Zimmermann G.R., Lehár J., Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12:34-42.